PTK2 and esophageal squamous cell carcinoma: To assess whether CAFs contribute to the resistance of FAK inhibitor in ESCC treatment in vivo, KYSE410 or KYSE510 cells and CAFs #1 or #5 were respectively coinjected into BALB/c-nu mice.